Fulgent Genetics Inc

Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. Its clinical diagnostic solutions include molecular diagnostic testing, genetic testing, anatomic pathology laboratory tests and services (such as gastrointestinal, dermatopathology, urologic, breast, neuropathology, and hematopathology), oncology tests and services, and sequencer services for hereditary cancer, reproductive health, and other diseases. Therapeutic development focuses on drug candidates for treating various cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates the Picture Genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems to help customers identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, large corporations, and patients. Formerly known as Fulgent Diagnostics, Inc., it changed its name to Fulgent Genetics, Inc. in August 2016. The company was founded in 2011 and is headquartered in El Monte, California.